 | • レポートコード：MRC2Q12-19154 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、129ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、免疫グロブリン静注（IVIg）療法のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 免疫グロブリン静注（IVIg）療法のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 免疫グロブリン静注（IVIg）療法の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 免疫グロブリン静注（IVIg）療法のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までの免疫グロブリン静注（IVIg）療法の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の免疫グロブリン静注（IVIg）療法の売上および2028年までの予測に焦点を当てています。 免疫グロブリン静注（IVIg）療法のグローバル主要企業には、TEIJIN LIMITED、Grifols、Biotest、Kamada、Takeda、Octapharma、Kedrion、LFB Group、Baxter、Nanyue Biopharming、Boya-Bio、CSL Plasma、CNBG、Beijing Tiantan Biological Products、Hualan Bio、Guangdong Shuagnlin Bio-pharmacy、Weiguang Biological、Sinopharm、Shanghai RAAS、Taibang Biologic Groupなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 免疫グロブリン静注（IVIg）療法市場は、タイプとアプリケーションによって区分されます。世界の免疫グロブリン静注（IVIg）療法市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 1g/20ml、1.25g/25ml、2.5g/50ml、5g/100ml、10g/200ml、その他 【アプリケーション別セグメント】 免疫不全、自己免疫疾患、急性感染症、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 免疫グロブリン静注（IVIg）療法製品概要 - タイプ別市場（1g/20ml、1.25g/25ml、2.5g/50ml、5g/100ml、10g/200ml、その他） - アプリケーション別市場（免疫不全、自己免疫疾患、急性感染症、その他） - 調査の目的 ・エグゼクティブサマリー - 世界の免疫グロブリン静注（IVIg）療法販売量予測2017-2028 - 世界の免疫グロブリン静注（IVIg）療法売上予測2017-2028 - 免疫グロブリン静注（IVIg）療法の地域別販売量 - 免疫グロブリン静注（IVIg）療法の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別免疫グロブリン静注（IVIg）療法販売量 - 主要メーカー別免疫グロブリン静注（IVIg）療法売上 - 主要メーカー別免疫グロブリン静注（IVIg）療法価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（1g/20ml、1.25g/25ml、2.5g/50ml、5g/100ml、10g/200ml、その他） - 免疫グロブリン静注（IVIg）療法のタイプ別販売量 - 免疫グロブリン静注（IVIg）療法のタイプ別売上 - 免疫グロブリン静注（IVIg）療法のタイプ別価格 ・アプリケーション別市場規模（免疫不全、自己免疫疾患、急性感染症、その他） - 免疫グロブリン静注（IVIg）療法のアプリケーション別販売量 - 免疫グロブリン静注（IVIg）療法のアプリケーション別売上 - 免疫グロブリン静注（IVIg）療法のアプリケーション別価格 ・北米市場 - 北米の免疫グロブリン静注（IVIg）療法市場規模（タイプ別、アプリケーション別） - 主要国別の免疫グロブリン静注（IVIg）療法市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの免疫グロブリン静注（IVIg）療法市場規模（タイプ別、アプリケーション別） - 主要国別の免疫グロブリン静注（IVIg）療法市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の免疫グロブリン静注（IVIg）療法市場規模（タイプ別、アプリケーション別） - 主要国別の免疫グロブリン静注（IVIg）療法市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の免疫グロブリン静注（IVIg）療法市場規模（タイプ別、アプリケーション別） - 主要国別の免疫グロブリン静注（IVIg）療法市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの免疫グロブリン静注（IVIg）療法市場規模（タイプ別、アプリケーション別） - 主要国別の免疫グロブリン静注（IVIg）療法市場規模（トルコ、サウジアラビア） ・企業情報 TEIJIN LIMITED、Grifols、Biotest、Kamada、Takeda、Octapharma、Kedrion、LFB Group、Baxter、Nanyue Biopharming、Boya-Bio、CSL Plasma、CNBG、Beijing Tiantan Biological Products、Hualan Bio、Guangdong Shuagnlin Bio-pharmacy、Weiguang Biological、Sinopharm、Shanghai RAAS、Taibang Biologic Group ・産業チェーン及び販売チャネル分析 - 免疫グロブリン静注（IVIg）療法の産業チェーン分析 - 免疫グロブリン静注（IVIg）療法の原材料 - 免疫グロブリン静注（IVIg）療法の生産プロセス - 免疫グロブリン静注（IVIg）療法の販売及びマーケティング - 免疫グロブリン静注（IVIg）療法の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 免疫グロブリン静注（IVIg）療法の産業動向 - 免疫グロブリン静注（IVIg）療法のマーケットドライバー - 免疫グロブリン静注（IVIg）療法の課題 - 免疫グロブリン静注（IVIg）療法の阻害要因 ・主な調査結果 |
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Product Name estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Intravenous Immunoglobulin(IVIg) Therapy is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Intravenous Immunoglobulin(IVIg) Therapy is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Intravenous Immunoglobulin(IVIg) Therapy is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key manufacturers of Intravenous Immunoglobulin(IVIg) Therapy include TEIJIN LIMITED, Grifols, Biotest, Kamada, Takeda, Octapharma, Kedrion, LFB Group and Baxter, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers’ production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Intravenous Immunoglobulin(IVIg) Therapy manufacturers, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Intravenous Immunoglobulin(IVIg) Therapy market. Further, it explains the major drivers and regional dynamics of the global Intravenous Immunoglobulin(IVIg) Therapy market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
TEIJIN LIMITED
Grifols
Biotest
Kamada
Takeda
Octapharma
Kedrion
LFB Group
Baxter
Nanyue Biopharming
Boya-Bio
CSL Plasma
CNBG
Beijing Tiantan Biological Products
Hualan Bio
Guangdong Shuagnlin Bio-pharmacy
Weiguang Biological
Sinopharm
Shanghai RAAS
Taibang Biologic Group
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by type and by application segments based on sales, price, and value for the period 2017-2028.
Intravenous Immunoglobulin(IVIg) Therapy Segment by Type
1g/20ml
1.25g/25ml
2.5g/50ml
5g/100ml
10g/200ml
Others
Intravenous Immunoglobulin(IVIg) Therapy Segment by Application
Immunodeficiency
Autoimmune Disease
Acute Infection
Others
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value and sales data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Intravenous Immunoglobulin(IVIg) Therapy market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Intravenous Immunoglobulin(IVIg) Therapy, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Intravenous Immunoglobulin(IVIg) Therapy, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Intravenous Immunoglobulin(IVIg) Therapy, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Intravenous Immunoglobulin(IVIg) Therapy sales, revenue, market share and industry ranking of main manufacturers, data from 2017 to 2022. Identification of the major stakeholders in the global Intravenous Immunoglobulin(IVIg) Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2017 to 2028. Evaluation and forecast the market size for Intravenous Immunoglobulin(IVIg) Therapy sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including TEIJIN LIMITED, Grifols, Biotest, Kamada, Takeda, Octapharma, Kedrion, LFB Group and Baxter, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Intravenous Immunoglobulin(IVIg) Therapy in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Intravenous Immunoglobulin(IVIg) Therapy manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country, sales and revenue for each segment.
Chapter 9: Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Intravenous Immunoglobulin(IVIg) Therapy sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
1 Study Coverage
1.1 Intravenous Immunoglobulin(IVIg) Therapy Product Introduction
1.2 Market by Type
1.2.1 Global Intravenous Immunoglobulin(IVIg) Therapy Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 1g/20ml
1.2.3 1.25g/25ml
1.2.4 2.5g/50ml
1.2.5 5g/100ml
1.2.6 10g/200ml
1.2.7 Others
1.3 Market by Application
1.3.1 Global Intravenous Immunoglobulin(IVIg) Therapy Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Immunodeficiency
1.3.3 Autoimmune Disease
1.3.4 Acute Infection
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Estimates and Forecasts 2017-2028
2.2 Global Intravenous Immunoglobulin(IVIg) Therapy Revenue Estimates and Forecasts 2017-2028
2.3 Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Region
2.4.1 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Region (2017-2022)
2.4.2 Global Sales Intravenous Immunoglobulin(IVIg) Therapy by Region (2023-2028)
2.5 Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Region
2.5.1 Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Region (2017-2022)
2.5.2 Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Manufacturers
3.1.1 Global Top Intravenous Immunoglobulin(IVIg) Therapy Manufacturers by Sales (2017-2022)
3.1.2 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Intravenous Immunoglobulin(IVIg) Therapy in 2021
3.2 Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Manufacturers
3.2.1 Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Manufacturers (2017-2022)
3.2.2 Global Intravenous Immunoglobulin(IVIg) Therapy Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Intravenous Immunoglobulin(IVIg) Therapy Revenue in 2021
3.3 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Intravenous Immunoglobulin(IVIg) Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Intravenous Immunoglobulin(IVIg) Therapy Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Type
4.1.1 Global Intravenous Immunoglobulin(IVIg) Therapy Historical Sales by Type (2017-2022)
4.1.2 Global Intravenous Immunoglobulin(IVIg) Therapy Forecasted Sales by Type (2023-2028)
4.1.3 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Market Share by Type (2017-2028)
4.2 Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Type
4.2.1 Global Intravenous Immunoglobulin(IVIg) Therapy Historical Revenue by Type (2017-2022)
4.2.2 Global Intravenous Immunoglobulin(IVIg) Therapy Forecasted Revenue by Type (2023-2028)
4.2.3 Global Intravenous Immunoglobulin(IVIg) Therapy Revenue Market Share by Type (2017-2028)
4.3 Global Intravenous Immunoglobulin(IVIg) Therapy Price by Type
4.3.1 Global Intravenous Immunoglobulin(IVIg) Therapy Price by Type (2017-2022)
4.3.2 Global Intravenous Immunoglobulin(IVIg) Therapy Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Application
5.1.1 Global Intravenous Immunoglobulin(IVIg) Therapy Historical Sales by Application (2017-2022)
5.1.2 Global Intravenous Immunoglobulin(IVIg) Therapy Forecasted Sales by Application (2023-2028)
5.1.3 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Market Share by Application (2017-2028)
5.2 Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Application
5.2.1 Global Intravenous Immunoglobulin(IVIg) Therapy Historical Revenue by Application (2017-2022)
5.2.2 Global Intravenous Immunoglobulin(IVIg) Therapy Forecasted Revenue by Application (2023-2028)
5.2.3 Global Intravenous Immunoglobulin(IVIg) Therapy Revenue Market Share by Application (2017-2028)
5.3 Global Intravenous Immunoglobulin(IVIg) Therapy Price by Application
5.3.1 Global Intravenous Immunoglobulin(IVIg) Therapy Price by Application (2017-2022)
5.3.2 Global Intravenous Immunoglobulin(IVIg) Therapy Price Forecast by Application (2023-2028)
6 North America
6.1 North America Intravenous Immunoglobulin(IVIg) Therapy Market Size by Type
6.1.1 North America Intravenous Immunoglobulin(IVIg) Therapy Sales by Type (2017-2028)
6.1.2 North America Intravenous Immunoglobulin(IVIg) Therapy Revenue by Type (2017-2028)
6.2 North America Intravenous Immunoglobulin(IVIg) Therapy Market Size by Application
6.2.1 North America Intravenous Immunoglobulin(IVIg) Therapy Sales by Application (2017-2028)
6.2.2 North America Intravenous Immunoglobulin(IVIg) Therapy Revenue by Application (2017-2028)
6.3 North America Intravenous Immunoglobulin(IVIg) Therapy Market Size by Country
6.3.1 North America Intravenous Immunoglobulin(IVIg) Therapy Sales by Country (2017-2028)
6.3.2 North America Intravenous Immunoglobulin(IVIg) Therapy Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Intravenous Immunoglobulin(IVIg) Therapy Market Size by Type
7.1.1 Europe Intravenous Immunoglobulin(IVIg) Therapy Sales by Type (2017-2028)
7.1.2 Europe Intravenous Immunoglobulin(IVIg) Therapy Revenue by Type (2017-2028)
7.2 Europe Intravenous Immunoglobulin(IVIg) Therapy Market Size by Application
7.2.1 Europe Intravenous Immunoglobulin(IVIg) Therapy Sales by Application (2017-2028)
7.2.2 Europe Intravenous Immunoglobulin(IVIg) Therapy Revenue by Application (2017-2028)
7.3 Europe Intravenous Immunoglobulin(IVIg) Therapy Market Size by Country
7.3.1 Europe Intravenous Immunoglobulin(IVIg) Therapy Sales by Country (2017-2028)
7.3.2 Europe Intravenous Immunoglobulin(IVIg) Therapy Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Intravenous Immunoglobulin(IVIg) Therapy Market Size by Type
8.1.1 Asia Pacific Intravenous Immunoglobulin(IVIg) Therapy Sales by Type (2017-2028)
8.1.2 Asia Pacific Intravenous Immunoglobulin(IVIg) Therapy Revenue by Type (2017-2028)
8.2 Asia Pacific Intravenous Immunoglobulin(IVIg) Therapy Market Size by Application
8.2.1 Asia Pacific Intravenous Immunoglobulin(IVIg) Therapy Sales by Application (2017-2028)
8.2.2 Asia Pacific Intravenous Immunoglobulin(IVIg) Therapy Revenue by Application (2017-2028)
8.3 Asia Pacific Intravenous Immunoglobulin(IVIg) Therapy Market Size by Region
8.3.1 Asia Pacific Intravenous Immunoglobulin(IVIg) Therapy Sales by Region (2017-2028)
8.3.2 Asia Pacific Intravenous Immunoglobulin(IVIg) Therapy Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Intravenous Immunoglobulin(IVIg) Therapy Market Size by Type
9.1.1 Latin America Intravenous Immunoglobulin(IVIg) Therapy Sales by Type (2017-2028)
9.1.2 Latin America Intravenous Immunoglobulin(IVIg) Therapy Revenue by Type (2017-2028)
9.2 Latin America Intravenous Immunoglobulin(IVIg) Therapy Market Size by Application
9.2.1 Latin America Intravenous Immunoglobulin(IVIg) Therapy Sales by Application (2017-2028)
9.2.2 Latin America Intravenous Immunoglobulin(IVIg) Therapy Revenue by Application (2017-2028)
9.3 Latin America Intravenous Immunoglobulin(IVIg) Therapy Market Size by Country
9.3.1 Latin America Intravenous Immunoglobulin(IVIg) Therapy Sales by Country (2017-2028)
9.3.2 Latin America Intravenous Immunoglobulin(IVIg) Therapy Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia
10 Middle East and Africa
10.1 Middle East and Africa Intravenous Immunoglobulin(IVIg) Therapy Market Size by Type
10.1.1 Middle East and Africa Intravenous Immunoglobulin(IVIg) Therapy Sales by Type (2017-2028)
10.1.2 Middle East and Africa Intravenous Immunoglobulin(IVIg) Therapy Revenue by Type (2017-2028)
10.2 Middle East and Africa Intravenous Immunoglobulin(IVIg) Therapy Market Size by Application
10.2.1 Middle East and Africa Intravenous Immunoglobulin(IVIg) Therapy Sales by Application (2017-2028)
10.2.2 Middle East and Africa Intravenous Immunoglobulin(IVIg) Therapy Revenue by Application (2017-2028)
10.3 Middle East and Africa Intravenous Immunoglobulin(IVIg) Therapy Market Size by Country
10.3.1 Middle East and Africa Intravenous Immunoglobulin(IVIg) Therapy Sales by Country (2017-2028)
10.3.2 Middle East and Africa Intravenous Immunoglobulin(IVIg) Therapy Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 TEIJIN LIMITED
11.1.1 TEIJIN LIMITED Corporation Information
11.1.2 TEIJIN LIMITED Overview
11.1.3 TEIJIN LIMITED Intravenous Immunoglobulin(IVIg) Therapy Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 TEIJIN LIMITED Intravenous Immunoglobulin(IVIg) Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 TEIJIN LIMITED Recent Developments
11.2 Grifols
11.2.1 Grifols Corporation Information
11.2.2 Grifols Overview
11.2.3 Grifols Intravenous Immunoglobulin(IVIg) Therapy Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Grifols Intravenous Immunoglobulin(IVIg) Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Grifols Recent Developments
11.3 Biotest
11.3.1 Biotest Corporation Information
11.3.2 Biotest Overview
11.3.3 Biotest Intravenous Immunoglobulin(IVIg) Therapy Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Biotest Intravenous Immunoglobulin(IVIg) Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Biotest Recent Developments
11.4 Kamada
11.4.1 Kamada Corporation Information
11.4.2 Kamada Overview
11.4.3 Kamada Intravenous Immunoglobulin(IVIg) Therapy Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Kamada Intravenous Immunoglobulin(IVIg) Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Kamada Recent Developments
11.5 Takeda
11.5.1 Takeda Corporation Information
11.5.2 Takeda Overview
11.5.3 Takeda Intravenous Immunoglobulin(IVIg) Therapy Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Takeda Intravenous Immunoglobulin(IVIg) Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Takeda Recent Developments
11.6 Octapharma
11.6.1 Octapharma Corporation Information
11.6.2 Octapharma Overview
11.6.3 Octapharma Intravenous Immunoglobulin(IVIg) Therapy Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Octapharma Intravenous Immunoglobulin(IVIg) Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Octapharma Recent Developments
11.7 Kedrion
11.7.1 Kedrion Corporation Information
11.7.2 Kedrion Overview
11.7.3 Kedrion Intravenous Immunoglobulin(IVIg) Therapy Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Kedrion Intravenous Immunoglobulin(IVIg) Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Kedrion Recent Developments
11.8 LFB Group
11.8.1 LFB Group Corporation Information
11.8.2 LFB Group Overview
11.8.3 LFB Group Intravenous Immunoglobulin(IVIg) Therapy Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 LFB Group Intravenous Immunoglobulin(IVIg) Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 LFB Group Recent Developments
11.9 Baxter
11.9.1 Baxter Corporation Information
11.9.2 Baxter Overview
11.9.3 Baxter Intravenous Immunoglobulin(IVIg) Therapy Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Baxter Intravenous Immunoglobulin(IVIg) Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Baxter Recent Developments
11.10 Nanyue Biopharming
11.10.1 Nanyue Biopharming Corporation Information
11.10.2 Nanyue Biopharming Overview
11.10.3 Nanyue Biopharming Intravenous Immunoglobulin(IVIg) Therapy Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Nanyue Biopharming Intravenous Immunoglobulin(IVIg) Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Nanyue Biopharming Recent Developments
11.11 Boya-Bio
11.11.1 Boya-Bio Corporation Information
11.11.2 Boya-Bio Overview
11.11.3 Boya-Bio Intravenous Immunoglobulin(IVIg) Therapy Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Boya-Bio Intravenous Immunoglobulin(IVIg) Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Boya-Bio Recent Developments
11.12 CSL Plasma
11.12.1 CSL Plasma Corporation Information
11.12.2 CSL Plasma Overview
11.12.3 CSL Plasma Intravenous Immunoglobulin(IVIg) Therapy Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 CSL Plasma Intravenous Immunoglobulin(IVIg) Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 CSL Plasma Recent Developments
11.13 CNBG
11.13.1 CNBG Corporation Information
11.13.2 CNBG Overview
11.13.3 CNBG Intravenous Immunoglobulin(IVIg) Therapy Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 CNBG Intravenous Immunoglobulin(IVIg) Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 CNBG Recent Developments
11.14 Beijing Tiantan Biological Products
11.14.1 Beijing Tiantan Biological Products Corporation Information
11.14.2 Beijing Tiantan Biological Products Overview
11.14.3 Beijing Tiantan Biological Products Intravenous Immunoglobulin(IVIg) Therapy Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Beijing Tiantan Biological Products Intravenous Immunoglobulin(IVIg) Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Beijing Tiantan Biological Products Recent Developments
11.15 Hualan Bio
11.15.1 Hualan Bio Corporation Information
11.15.2 Hualan Bio Overview
11.15.3 Hualan Bio Intravenous Immunoglobulin(IVIg) Therapy Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Hualan Bio Intravenous Immunoglobulin(IVIg) Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Hualan Bio Recent Developments
11.16 Guangdong Shuagnlin Bio-pharmacy
11.16.1 Guangdong Shuagnlin Bio-pharmacy Corporation Information
11.16.2 Guangdong Shuagnlin Bio-pharmacy Overview
11.16.3 Guangdong Shuagnlin Bio-pharmacy Intravenous Immunoglobulin(IVIg) Therapy Sales, Price, Revenue and Gross Margin (2017-2022)
11.16.4 Guangdong Shuagnlin Bio-pharmacy Intravenous Immunoglobulin(IVIg) Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Guangdong Shuagnlin Bio-pharmacy Recent Developments
11.17 Weiguang Biological
11.17.1 Weiguang Biological Corporation Information
11.17.2 Weiguang Biological Overview
11.17.3 Weiguang Biological Intravenous Immunoglobulin(IVIg) Therapy Sales, Price, Revenue and Gross Margin (2017-2022)
11.17.4 Weiguang Biological Intravenous Immunoglobulin(IVIg) Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 Weiguang Biological Recent Developments
11.18 Sinopharm
11.18.1 Sinopharm Corporation Information
11.18.2 Sinopharm Overview
11.18.3 Sinopharm Intravenous Immunoglobulin(IVIg) Therapy Sales, Price, Revenue and Gross Margin (2017-2022)
11.18.4 Sinopharm Intravenous Immunoglobulin(IVIg) Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.18.5 Sinopharm Recent Developments
11.19 Shanghai RAAS
11.19.1 Shanghai RAAS Corporation Information
11.19.2 Shanghai RAAS Overview
11.19.3 Shanghai RAAS Intravenous Immunoglobulin(IVIg) Therapy Sales, Price, Revenue and Gross Margin (2017-2022)
11.19.4 Shanghai RAAS Intravenous Immunoglobulin(IVIg) Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.19.5 Shanghai RAAS Recent Developments
11.20 Taibang Biologic Group
11.20.1 Taibang Biologic Group Corporation Information
11.20.2 Taibang Biologic Group Overview
11.20.3 Taibang Biologic Group Intravenous Immunoglobulin(IVIg) Therapy Sales, Price, Revenue and Gross Margin (2017-2022)
11.20.4 Taibang Biologic Group Intravenous Immunoglobulin(IVIg) Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.20.5 Taibang Biologic Group Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Intravenous Immunoglobulin(IVIg) Therapy Industry Chain Analysis
12.2 Intravenous Immunoglobulin(IVIg) Therapy Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Intravenous Immunoglobulin(IVIg) Therapy Production Mode & Process
12.4 Intravenous Immunoglobulin(IVIg) Therapy Sales and Marketing
12.4.1 Intravenous Immunoglobulin(IVIg) Therapy Sales Channels
12.4.2 Intravenous Immunoglobulin(IVIg) Therapy Distributors
12.5 Intravenous Immunoglobulin(IVIg) Therapy Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Intravenous Immunoglobulin(IVIg) Therapy Industry Trends
13.2 Intravenous Immunoglobulin(IVIg) Therapy Market Drivers
13.3 Intravenous Immunoglobulin(IVIg) Therapy Market Challenges
13.4 Intravenous Immunoglobulin(IVIg) Therapy Market Restraints
14 Key Findings in The Global Intravenous Immunoglobulin(IVIg) Therapy Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer